Sector
PharmaceuticalsOpen
₹719.8Prev. Close
₹725.75Turnover(Lac.)
₹653.78Day's High
₹749Day's Low
₹70652 Week's High
₹731.5552 Week's Low
₹263.55Book Value
₹256.61Face Value
₹10Mkt Cap (₹ Cr.)
2,626.76P/E
0EPS
0Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|
Equity Capital | 36 | 36 | 35.93 | 122.85 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,467.13 | 1,491.05 | 1,556.86 | 967.94 |
Net Worth | 1,503.13 | 1,527.05 | 1,592.79 | 1,090.79 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Revenue | 1,268.34 | 1,616.88 | 1,321.75 | 560.4 |
yoy growth (%) | -21.55 | 22.32 | 135.85 | |
Raw materials | -653.89 | -724.41 | -598.87 | -293.32 |
As % of sales | 51.55 | 44.8 | 45.3 | 52.34 |
Employee costs | -234.2 | -227.63 | -202.24 | -69.51 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Profit before tax | -88.17 | 220.96 | 112.49 | 1.95 |
Depreciation | -112.01 | -108.31 | -93.67 | -36.55 |
Tax paid | 33.1 | 0 | 0 | 0 |
Working capital | 200.65 | 302.71 | 157.99 | |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | -21.55 | 22.32 | 135.85 | |
Op profit growth | -79.14 | 50.2 | 317.87 | |
EBIT growth | -104.22 | 60.44 | 601.98 | |
Net profit growth | -126.5 | 96.42 | 5,668.71 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 1,288.92 | 1,443.81 | 1,268.34 | 1,616.88 | 1,321.75 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 1,288.92 | 1,443.81 | 1,268.34 | 1,616.88 | 1,321.75 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 5.37 | 22.55 | 20.02 | 28.77 | 27.52 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,775.75 | 150.91 | 4,20,027.58 | 237.82 | 0.77 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,855.95 | 78.49 | 1,30,370.29 | 430 | 0.61 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,574.55 | 32.24 | 1,28,058.81 | 1,055.94 | 0.82 | 3,752.25 | 346.4 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,178.7 | 27.87 | 1,21,729.16 | 1,700.8 | 0.25 | 4,035.4 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,954.5 | 28.24 | 1,16,346.95 | 1,417.2 | 0.57 | 5,823.9 | 1,458.7 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Non Executive Dir.
Aditya Puri
Independent Non Exe. Director
Nirmal P Bhogilal
Independent Non Exe. Director
Vineeta Rai
Independent Non Exe. Director
RAJAGOPALAN RAMAKRISHNAN
Independent Non Exe. Director
Kausalya Santhanam
Non Executive Director
ANKUR NAND THADANI
Non Executive Director
Arun Kumar
Executive Director & CFO
S Hariharan
Managing Director & CEO
Jitesh Devendra
Managing Director & CEO
Poorvank Purohit
Additional Director
Rajendra Kumar Srivastava
Additional Director
Rajiv Vijay Naba
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Solara Active Pharma Sciences Ltd
Summary
Solara Active Pharma Sciences Ltd is a Public Limited Company incorporated in February 23, 2017 under the provisions of Companies Act, 2013 to undertake business in manufacturing, production, processing, formulating, sale, import, export, merchandising, distributing, trading of and dealing in active pharmaceutical ingredients (APIs). The Company has six APIs manufacturing plants located in Ambernath, Mangalore, Mysore, Puducherry, Vishakhapatnam, and Cuddalore with a capacity of over 2,000 kilo litres and two R&D Centres in Chennai and Bangalore. The business is spread across 75 countries globally with extensive operations in key markets of North America, Europe, Japan, South Korea, the Middle East and North Africa.The Company offer rich basket of niche high-value products for global markets. The Company has developed 80+ commercial APIs predominantly in anthelmintic, anti-malarias, anti-infective, neuromuscular insomnia and anti-psychotic hyperkalemia segments, among others. It also reinforce entry barriers to competition and build strong intrinsic value through market specific launches. Apart from this, the Solara Active has two research and development units - in Bengaluru and Chennai - equipped with state-of-the-art facilities and a pipeline of 25+ products, at different stages of development. These drugs primarily deal with anthelmintic, anti-malarias, beta blockers,muscle relaxants, novel oral anticoagulants, anti-infective and other niche segments.The Companys manufact
Read More
The Solara Active Pharma Sciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹729.55 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Solara Active Pharma Sciences Ltd is ₹2626.76 Cr. as of 23 Aug ‘24
The PE and PB ratios of Solara Active Pharma Sciences Ltd is 0 and 2.75 as of 23 Aug ‘24
The 52-week high/low is the highest and lowest price at which a Solara Active Pharma Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Solara Active Pharma Sciences Ltd is ₹263.55 and ₹731.55 as of 23 Aug ‘24
Solara Active Pharma Sciences Ltd's CAGR for 5 Years at 12.88%, 3 Years at -21.21%, 1 Year at 120.76%, 6 Month at 62.74%, 3 Month at 49.53% and 1 Month at 26.18%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.